Amivantamab: A narrative drug review
Epidermal growth factor receptor (EGFR) activating mutations are known oncogenic drivers in non-small-cell lung cancer (NSCLC), with 85% attributable to an exon 19 deletion or exon 21 L858R point substitution. The next most common is an exon 20 insertion mutation (Ex20Ins), which results in an alter...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Sarja: | Cancer Research, Statistics, and Treatment |
| Aiheet: | |
| Linkit: | http://www.crstonline.com/article.asp?issn=2590-3233;year=2023;volume=6;issue=2;spage=261;epage=271;aulast=John |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|